Author:
Sinnott Jennifer A.,Torkashvand Elaheh,Meade Caitlin E.,Salani Ritu,Vetter Monica Hagan,Hall Bobbie,Skolnick Rebecca,Bixel Kristin L.,Cohn David E.,Cosgrove Casey M.,Copeland Larry J.,Hebert Courtney,Felix Ashley S.
Abstract
Abstract
Purpose
We examined associations between patient and treatment characteristics with longitudinally collected patient-reported outcome (PRO) measures to provide a data-informed description of the experiences of women undergoing treatment for endometrial cancer.
Methods
We administered National Institutes of Health Patient Reported Outcomes Measurement Information System (PROMIS) questionnaires at the preoperative visit and at 6 and 12 months after surgery. Anxiety, depression, fatigue, sleep disturbance, pain, physical function, and ability to participate in social roles were assessed. Analysis of variance (ANOVA) and linear mixed models were used to examine associations between patient characteristics and PRO measures at baseline and through time.
Results
Of 187 women enrolled, 174 (93%) and 103 (69%) completed the 6- and 12-month questionnaires, respectively. Anxiety was substantially elevated at baseline (half of one population-level standard deviation) and returned to general population mean levels at 6 and 12 months. Younger age, Medicaid/None/Self-pay insurance, prevalent diabetes, and current smoking were associated with higher symptom burden on multiple PRO measures across the three time points. Women with aggressive histology, higher disease stage, or those with adjuvant treatment had worse fatigue at 6 months, which normalized by 12 months.
Conclusions
We observed a high symptom burden at endometrial cancer diagnosis, with most PRO measures returning to general population means by 1 year. Information on risk factor-PRO associations can be used during the clinical visit to inform supportive service referral.
Implications for Cancer Survivors
These findings can inform clinicians’ discussions with endometrial cancer survivors regarding expected symptom trajectory following diagnosis and treatment.
Funder
Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Publisher
Springer Science and Business Media LLC